{"entity":{"id":"nct07802834","kind":"trial","name":"Adjuvant ctDNA-Adapted Treatment With Zipalertinib in Early-Stage Atypical EGFR-Mutant NSCLC","aka":[],"tldr":"A phase 2 trial of zipalertinib in lung cancer, run by Stanford University, not yet recruiting.","summary":"Adjuvant ctDNA-Adapted Treatment With Zipalertinib in Early-Stage Atypical EGFR-Mutant NSCLC is a phase 2, interventional study registered as NCT07802834 by Stanford University, with a registry enrolment figure of 42 participants, started 2026-11 and due to reach its primary completion in 2028-12. Interventions recorded: Zipalertinib. Conditions listed: EGFR; Lung Cancer (NSCLC); Non Small Cell Lung Cancer. Primary outcome: Molecular response rate at 12 weeks. Lung eligibility wording from the registry: \"Histological documentation of NSCLC (squamous histology is permitted)\". No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT07802834","url":"https://clinicaltrials.gov/study/NCT07802834"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["egfr-mutant-nsclc","resectable-nsclc"],"sections":[],"technologies":["mrd-testing"],"targets":[],"drugs":["zipalertinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07802834","phase":"2","setting":"Adjuvant ctDNA-Adapted Personalized Treatment With Zipalertinib in Early-Stage Atypical EGFR-Mutant NSCLC","sponsor":"Stanford University","enrolled":42,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07802834/","neighbours":{"cancer":[{"id":"egfr-mutant-nsclc","kind":"cancer","name":"EGFR-mutated non-small-cell lung cancer","route":"/cancers/egfr-mutant-nsclc/"},{"id":"resectable-nsclc","kind":"cancer","name":"Resectable stage I to III non-small-cell lung cancer","route":"/cancers/resectable-nsclc/"}],"technology":[{"id":"mrd-testing","kind":"technology","name":"MRD / molecular residual disease testing","route":"/technologies/mrd-testing/"}],"drug":[{"id":"zipalertinib","kind":"drug","name":"Zipalertinib","route":"/drugs/zipalertinib/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}